The Technical Analyst
IGM Biosciences Inc [IGMS]
Exchange: NASDAQ Sector: Healthcare Industry: Biotechnology
IGM Biosciences Inc Price, Forecast, Insider, Ratings, Fundamentals & Signals
Current Signal: BUY (auto-tracking)
-6.25% $6.75
America/New_York / 22 apr 2024 @ 16:00
| FUNDAMENTALS | |
|---|---|
| MarketCap: | 397.90 mill |
| EPS: | -4.71 |
| P/E: | -1.430 |
| Earnings Date: | May 10, 2024 |
| SharesOutstanding: | 58.95 mill |
| Avg Daily Volume: | 0.261 mill |
| RATING 2024-04-22 |
|---|
| B |
| Neutral |
| RATINGS | ||
|---|---|---|
| Rating CashFlow: | Neutral | |
| Return On Equity: | Strong Sell | |
| Return On Asset: | Sell | |
| DE: | Buy | |
| P/E: | Sell | |
| Price To Book: | Buy |
| QUARTER GROWTHS | ||||||
|---|---|---|---|---|---|---|
| 3/22 | 4/22 | 1/23 | 2/23 | 3/23 | 4/23 | |
| Revenue | ||||||
| Gr.Profit | ||||||
| Ebit | ||||||
| Asset | ||||||
| Debt |
| PE RATIO: COMPANY / SECTOR |
|---|
| 0.00x |
| Company: PE -1.430 | sector: PE -3.05 |
| PE RATIO: COMPANY / INDUSTRY |
|---|
| -0.24x |
| Company: PE -1.430 | industry: PE 5.88 |
| DISCOUNTED CASH FLOW VALUE |
|---|
|
$0.806 (-88.06%) $-5.94 |
| Date: 2024-04-23 |
| Expected Trading Range (DAY) |
|---|
|
$ 5.75 - 7.81 ( +/- 15.22%) |
| ATR Model: 14 days |
Insider Trading
| Date | Person | Action | Amount | type |
|---|---|---|---|---|
| 2024-03-29 | Lee Michael Stewart | Buy | 1 734 | Common Stock |
| 2024-03-29 | Topsoe Jakob Haldor | Buy | 1 734 | Common Stock |
| 2024-03-29 | Topsoe Christina Teng | Buy | 2 687 | Common Stock |
| 2024-03-29 | Thompson Elizabeth H.z. | Buy | 1 452 | Common Stock |
| 2024-03-29 | Behrens M Kathleen | Buy | 3 078 | Common Stock |
| INSIDER POWER |
|---|
| 84.80 |
| Last 99 transactions |
| Buy: 2 359 277 | Sell: 195 552 |
Forecast:
16:00 - $6.77
Live Trading Signals (every 1 min)
Forecast
1: 16:00 - $6.77
Forecast 2: 16:00 - $6.77
Forecast 3: 16:00 - $6.77
SCORE
10.00
Buy
10.00
Buy
Score Algorithm Version: 1.2C
Last version updated: Fri April 15th, 2022
Last version updated: Fri April 15th, 2022
| Indicator Signals | |
|---|---|
| RSI 21 | |
| SMA | |
| Trend | |
| Trend 2 | |
| Trend 3 | |
| MACD |
| Volume Signals | |
|---|---|
| Price | $6.75 (-6.25% ) |
| Volume | 0.238 mill |
| Avg. Vol. | 0.261 mill |
| % of Avg. Vol | 91.23 % |
| Signal 1: | |
| Signal 2: |
Today
Last 12 Months
RSI
Last 10 Buy & Sell Signals For IGMS
0 Signals | Accuracy: 0.00% | Accuracy Buy: 0.00% | Accuracy Sell: 0.00%
Avg return buy: 0.00 % | Avg return sell: 0.00 %
$1 invested is now $1.00 or 0.00% since Coming Soon
| Date | Signal | @ | Closed | % | Feb 8 - 15:34 | buy | $13.06 | N/A | Active |
|---|
IGMS
IGM Biosciences, Inc., a biotechnology company, develops Immunoglobulin M (IgM) antibodies for the treatment of cancer, infectious diseases, and autoimmune and inflammatory diseases. The company's lead product candidate is IGM-2323, a bispecific IgM antibody that is in Phase 2 clinical trials to treat patients with relapsed/refractory B cell Non-Hodgkin's lymphoma (NHL). It is also developing IGM-8444, an IgM antibody, which is in Phase 1 clinical trials for the treatment of patients with solid cancers; and IGM-7354, an anti-PD-L1 IgM antibody for the treatment of patients with solid and hematologic malignancies; IGM-2644, a bispecific T cell engaging IgM antibody targeting CD38 and CD3 proteins for the treatment of patients with multiple myeloma; and IGM-2537, a bispecific T cell engaging IgM antibody targeting CD123 and CD3 proteins for the treatment of patients with acute myeloid leukemia, myelodysplastic syndromes, and acute lymphoblastic leukemia. It has a collaboration and license agreement with Genzyme Corporation to generate, develop, manufacture, and commercialize IgM antibodies. The company was formerly known as Palingen, Inc. and changed its name to IGM Biosciences, Inc. in 2010. IGM Biosciences, Inc. was incorporated in 1993 and is headquartered in Mountain View, California.
Last 10 Buy Signals
Latest Press Releases
2024-04-17 08:30:00 - Press Release
Igm Biosciences Announces Refocusing Of Sanofi Collaboration
Agreement focuses on immunology/inflammation, aligning with sanofi's ongoing commitment to advancing therapies for patients across multiple inflammatory diseases agreement focuses on immunology/inflammation, aligning with sanofi's ongoing commitment to advancing therapies for patients across multiple inflammatory diseases
2024-04-10 07:00:00 - Press Release
Igm Biosciences To Present At The Stifel 2024 Virtual Targeted Oncology Forum
Mountain view, calif., april 10, 2024 (globe newswire) -- igm biosciences, inc. (nasdaq: igms), a clinical-stage biotechnology company creating and developing engineered igm antibodies, today announced that fred schwarzer, chief executive officer, will participate in a fireside chat at the stifel 2024 virtual targeted oncology forum on wednesday, april 17, 2024, at 12:00 p.m. edt.
2024-03-07 16:10:00 - Press Release
Igm Biosciences Announces Fourth Quarter And Full Year 2023 Financial Results And Provides corporate Update
Mountain view, calif., march 07, 2024 (globe newswire) -- igm biosciences, inc. (nasdaq: igms), a clinical-stage biotechnology company creating and developing engineered igm antibodies, today announced its financial results for the fourth quarter and full year ended december 31, 2023 and provided an update on recent developments.
2024-02-01 07:00:00 - Press Release
Igm Biosciences To Present At The Guggenheim Healthcare Talks 6th Annual Biotechnology Conference
Mountain view, calif., feb. 01, 2024 (globe newswire) -- igm biosciences, inc. (nasdaq: igms), a clinical-stage biotechnology company creating and developing engineered igm antibodies, today announced that fred schwarzer, chief executive officer, will participate in a fireside chat at the guggenheim healthcare talks 6th annual biotechnology conference on thursday, february 8, 2024, at 2:30 p.m. est in new york.
2024-01-03 07:00:00 - Press Release
Igm Biosciences To Present At The 42nd Annual J.p. Morgan Healthcare Conference
Mountain view, calif., jan. 03, 2024 (globe newswire) -- igm biosciences, inc. (nasdaq: igms), a clinical-stage biotechnology company creating and developing engineered igm antibodies, today announced that fred schwarzer, chief executive officer, will present at the 42nd annual j.p. morgan healthcare conference on wednesday, january 10, 2024, at 11:15 a.m. pst in san francisco.
Latest News
2024-03-07 18:46:13 - Zacks Investment Research
IGM Biosciences, Inc. (IGMS) Reports Q4 Loss, Lags Revenue Estimates
IGM Biosciences, Inc. (IGMS) came out with a quarterly loss of $1.01 per share versus the Zacks Consensus Estimate of a loss of $1.06. This compares to loss of $1.19 per share a year ago.
2024-03-01 10:56:09 - Zacks Investment Research
Wall Street Analysts Think IGM Biosciences, Inc. (IGMS) Could Surge 63.1%: Read This Before Placing a Bet
The average of price targets set by Wall Street analysts indicates a potential upside of 63.1% in IGM Biosciences, Inc. (IGMS). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.
2024-02-14 10:56:09 - Zacks Investment Research
Wall Street Analysts Believe IGM Biosciences, Inc. (IGMS) Could Rally 35.08%: Here's is How to Trade
The consensus price target hints at a 35.1% upside potential for IGM Biosciences, Inc. (IGMS). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.
2024-02-01 07:00:00 - GlobeNewsWire
IGM Biosciences to Present at the Guggenheim Healthcare Talks 6th Annual Biotechnology Conference
MOUNTAIN VIEW, Calif., Feb. 01, 2024 (GLOBE NEWSWIRE) -- IGM Biosciences, Inc. (Nasdaq: IGMS), a clinical-stage biotechnology company creating and developing engineered IgM antibodies, today announced that Fred Schwarzer, Chief Executive Officer, will participate in a fireside chat at the Guggenheim Healthcare Talks 6th Annual Biotechnology Conference on Thursday, February 8, 2024, at 2:30 p.m. EST in New York.
2024-01-16 09:47:09 - Zacks Investment Research
IGM Bio (IGMS) Stock Rallies 142% in 3 Months: Here's Why
IGM Bio (IGMS) stock surges 142% in the past three months on strategic reprioritization efforts to focus its resources on the development of pipeline candidates for cancer and autoimmune indications.
2024-01-03 07:00:00 - GlobeNewsWire
IGM Biosciences to Present at the 42nd Annual J.P. Morgan Healthcare Conference
MOUNTAIN VIEW, Calif., Jan. 03, 2024 (GLOBE NEWSWIRE) -- IGM Biosciences, Inc. (Nasdaq: IGMS), a clinical-stage biotechnology company creating and developing engineered IgM antibodies, today announced that Fred Schwarzer, Chief Executive Officer, will present at the 42nd Annual J.P. Morgan Healthcare Conference on Wednesday, January 10, 2024, at 11:15 a.m. PST in San Francisco.
2023-12-06 02:44:00 - PRNewsWire
Medivir to present at the Carlsquare Equity Research Investor Day
STOCKHOLM , Dec. 6, 2023 /PRNewswire/ -- Medivir AB (Nasdaq Stockholm: MVIR), a pharmaceutical company focused on developing innovative treatments for cancer in areas of high unmet medical need, announces that the company will present at the Carlsquare Equity Research Investor Day, today December 6, 2023. CEO Jens Lindberg will present at 14.30 CET, with focus on the latest developments and the company's future plans.
2023-11-22 02:46:00 - PRNewsWire
Medivir to present at the Redeye Life Science Day
STOCKHOLM , Nov. 22, 2023 /PRNewswire/ -- Medivir AB (NASDAQ Stockholm: MVIR), a pharmaceutical company focused on developing innovative treatments for cancer in areas of high unmet medical need, announces that the company will participate at the Redeye Life Science Day, tomorrow November 23, 2023. CEO Jens Lindberg will participate in an In Focus interview at 13.20 CET, led by Redeye analyst Richard Ramanius, with focus on the latest developments and the company's future plans.
2023-11-21 02:48:00 - PRNewsWire
Medivir to present at the Erik Penser Bank Company Event
STOCKHOLM , Nov. 21, 2023 /PRNewswire/ -- Medivir AB (Nasdaq Stockholm: MVIR), a pharmaceutical company focused on developing innovative treatments for cancer in areas of high unmet medical need, announces that the company will present at the Erik Penser Bank Company Event on Thursday, November 23, at 10.10 CET. CEO Jens Lindberg will present and answer questions about the latest developments and the company's future plans.
2023-11-16 11:16:33 - Zacks Investment Research
Does IGM Biosciences, Inc. (IGMS) Have the Potential to Rally 268.31% as Wall Street Analysts Expect?
The average of price targets set by Wall Street analysts indicates a potential upside of 268.3% in IGM Biosciences, Inc. (IGMS). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.